Main histologic types of non–small-cell lung cancer differ in expression of prognosis-related genes

…, E Jassem, A Szymanowska-Narloch… - Clinical lung cancer, 2013 - Elsevier
Background There is increasing evidence that suggests that particular histopathologic types
of non–small-cell lung cancer (NSCLC) display distinct molecular characteristics. We …

[HTML][HTML] IPF Respiratory Symptoms Management—Current Evidence

P Janowiak, A Szymanowska-Narloch… - Frontiers in …, 2022 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic disease of the lungs which is
characterized by heavy symptom burden, especially in the last year of life. Despite recently …

[PDF][PDF] Atypical manifestations of granulomatosis with polyangiitis: the diagnostic challenge for pulmonologists

A Szymanowska-Narloch, D Gawryluk… - Advances in …, 2019 - journals.viamedica.pl
This is a review considering atypical manifestations of granulomatosis with polyangiitis (GPA).
Virtually any organ can be affected, and in some patients, GPA can manifest unusually. …

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors

M Skrzypski, A Szymanowska-Narloch… - Contemporary …, 2017 - termedia.pl
Non-small cell lung cancer (NSCLC) driven by activating mutations in epidermal growth
factor receptor (EGFR) constitutes up to 10% of NSCLC cases. According to the NCCN …

Choroba śródmiąższowa płuc w przebiegu układowych chorób tkanki łącznej—wspólny problem reumatologa i pulmonologa

…, Ż Smoleńska, A Szymanowska-Narloch… - Varia …, 2022 - journals.viamedica.pl
Choroba śródmiąższowa płuc jest częstym i niebezpiecznym powikłaniem wielu chorób
reumatologicznych. Dzięki postępowi, jaki dokonał się w ciągu ostatnich lat, wzrosły możliwości …

Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis? Real-world results from the EMPIRE registry

…, J Tekavec-Trkanjec, A Szymanowska-Narloch… - 2017 - Eur Respiratory Soc
Aims: Many patients with idiopathic pulmonary fibrosis (IPF) have a delay in diagnosis and
thus also in treatment. We investigated whether such delay influenced survival and treatment …

Analysis of comorbid conditions in 1210 IPF patients from the EMPIRE registry

…, J Tekavec-Trkanjec, A Szymanowska-Narloch… - 2017 - Eur Respiratory Soc
Most patients with IPF have comorbidities, which affect functional status, quality of life and
survival. Our study aims are to analyze comorbidities in a series of 1210 IPF patients from the …

IPF Respiratory Symptoms Management—Evidence Current

P Janowiak, A Szymanowska-Narloch… - Palliative care for …, 2023 - books.google.com
Idiopathic pulmonary fibrosis (IPF) is the most frequent idiopathic interstitial pneumonia and
one of the most frequent interstitial lung diseases (ILD)(1). It is a chronic, progressive …

Idiopathic pulmonary fibrosis (IPF) patients in Poland–preliminary cohort analysis of EMPIRE registry

…, P Sliwinski, S Majewski, A Szymanowska-Narloch… - 2017 - Eur Respiratory Soc
Epidemiological data on IPF patients in Poland is scarce. There is no national registry of IPF
cases. Facing the possibility of antifibrotic treatment opportunities, knowledge of the …

Interstitial lung disease in the course of systemic connective tissue diseases: A common problem for rheumatologists and pulmonologists

…, Ż Smoleńska, A Szymanowska-Narloch… - Rheumatology …, 2022 - journals.viamedica.pl
Interstitial lung disease is a common and dangerous complication of many rheumatic
diseases. Progress over the last several years has increased diagnostic capabilities, led to …